Acetyl l-carnitine (ALC) treatment in elderly patients with fatigue

Malaguarnera, Michele; Gargante, Maria Pia; Cristaldi, Erika; Colonna, Valentina; Messano, Masa; Koverech, Aleardo; Neri, Sergio; Vacante, Marco; Cammalleri, Lisa; Motta, Massimo

doi:10.1016/j.archger.2007.03.012

Cited by 70 publications

(38 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In total, 3.4% of the patients withdrew from the study due to adverse reactions. These results demonstrate that ALC is well tolerated in patients, which is consistent with previous studies (24)(25)(26)(27). Seven cases of SAE [two in the trial group (1.7%) and five in the control group (4.2%)] were recorded, although none of the SAEs were determined to be associated with drug administration.…”

Section: Full Analysis Set Per-protocol Set -------------------------supporting

confidence: 79%

A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy

Sun

Shu

Liu

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The present study aimed to evaluate the efficacy and safety of acetyl-L-carnitine (ALC) for the treatment of chemotherapy-induced peripheral neuropathy (CIPN). The study was carried out as a prospective, randomized, double-blind, placebo-controlled and paralleled clinical study. A total of 239 patients with CIPN were selected as the study subjects. Of the 239 subjects, 118 subjects received 3 g/day ALC orally for 8 weeks and 121 received a placebo. The primary endpoint was improvement of peripheral neuropathy by at least one grade. Patient status was assessed at week 4, 8 and 12 after enrollment into the study. In both the full analysis set (FAS) and the per-protocol set (PPS), peripheral sensory neuropathy was significantly ameliorated in the ALC group with 50.5 and 51.6% patients meeting the primary endpoint at week 8, compared with 24.1 and 23.1% of patients in the placebo group (P<0.001 in both sets). Secondary endpoints, such as the nerve electrophysiological examination and the Karnofsky physical score were also significantly improved in patients receiving ALC treatment, as compared with the placebo group (FAS, P= 0.0463 and P= 0.022; PPS, P= 0.0076 and P= 0.0064, respectively). Cancer-associated fatigue was significantly alleviated following ALC treatment in the PPS (P= 0.0135). In the safety analysis set, the difference in adverse events incidence between the two groups was not statistically significant (P= 0.3903). There were only two severe adverse events in the ALC group, which were not associated with the effect of ALC. In conclusion, the results of the present study demonstrated that in Chinese patients with cancer, oral administration of ALC is effective at ameliorating peripheral sensory neuropathy induced by chemotherapy, as well as reducing of cancer-associated fatigue and improving physical conditions.

show abstract

Section: Full Analysis Set Per-protocol Set -------------------------supporting

confidence: 79%

A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy

Sun

Shu

Liu

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Abnormal mitochondria have been observed in muscle of some elderly patients with fatigue, suggesting some underlying abnormalities in muscle mitochondrial energy production (Behan et al, 1991). The ALC treatment reduced significantly both physical and mental fatigue and improved physical activity and cognitive status (Malaguarnera et al, 2007). The improvement of energetic metabolism in myocardial tissue and in muscular-skeletal tissue is probably the factor that reduces the presence and the severity of physical fatigue in treated subjects.…”

Section: Fatiguementioning

confidence: 99%

Metabolic Modulators to Treat Cardiac Arrhythmias Induced by Ischemia and Reperfusion

Najafi¹,

Eteraf-Oskouei²

2012

Tachycardia

View full text Add to dashboard Cite

“…Although most of colorectal patient were able to work, lower levels of productivity, lower work ability and reduced job retention have been reported. An adequate supportive therapy of fatigue [22][23][24] could increase work productivity and health-related quality of life. Future studies are needed to investigate the relation among job, cancer, and related cancer treatment, and develop innovative approaches at the workplace to address these areas realistically and head on.…”

Section: Discussionmentioning

confidence: 99%

Work Productivity and Activity Impairment in Colorectal Cancer Patients Treated with Capecitabine

Malaguarnera¹,

Pennisi²,

Grosso³

et al. 2013

JCT

Self Cite

View full text Add to dashboard Cite

Background: The employment status of workers with cancer has important implications for impairment of intimate and family relationships and for economic, social and psychological health. The aim of the present study was to evaluate the effect of chemotherapy with capecitabine in patients with colorectal cancer on work productivity and daily activity. Methods: 30 patients with primary diagnosis of stage III colorectal cancer were enrolled for our study. All patients received capecitabine twice daily at a cumulative dose of 2500 mg/m 2 on days 1 -14 and repeated on day 22. Work productivity was determined using the WPAI questionnaire. Results: We observed a significant increase in absenteeism after 1 cycle, after 6 cycles of therapy and at follow-up (p < 0.001). On the other hand, presenteeism, work productivity loss and daily activity impairment, increased after 1 cycle and 6 cycles of therapy, but we could not find statistically different significances. Conclusions: Colorectal cancer diagnosis and treatment are associated with frailty and vulnerability. Chemotherapy with capecitabine may result in negative consequences for job performance.

show abstract

Acetyl l-carnitine (ALC) treatment in elderly patients with fatigue

Cited by 70 publications

References 35 publications

A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy

A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy

Metabolic Modulators to Treat Cardiac Arrhythmias Induced by Ischemia and Reperfusion

Work Productivity and Activity Impairment in Colorectal Cancer Patients Treated with Capecitabine

Contact Info

Product

Resources

About